REDWOOD CITY, Calif., June 25 /PRNewswire/ -- MyoScience(R), Inc. today announced that Joseph E. Whitters, CPA former chairman of the board of Mentor Corporation, was elected to the MyoScience board of directors. Whitters joined the Mentor board in 2004, assuming the Chairman role soon thereafter. Mentor was acquired by Johnson and Johnson (JNJ) in 2009 for $1.1 Billion. He also serves on the boards of directors of Omnicell, Luminent Mortgage Capital, and several private companies. From 1986 to 2005, Mr. Whitters was an executive at First Health, serving as CFO for most of his tenure. During that period the company’s revenues grew from $5 to $900 Million. It was acquired by Coventry Health Plans in 2005 for $1.8 Billion.
“Joe Whitters has an exceptionally strong financial and operational background. Additionally, he has a deep industry experience in the health care and aesthetics areas. This very relevant experience and his critical insight into the aesthetics market will greatly benefit a company at MyoScience’s stage,” said Bob Curtis, MyoScience CEO.
“I believe MyoScience has some very innovative and unique aesthetics technologies,” said Whitters. “I look forward to working with this dynamic team and the board.”
Whitters will fill a board seat left vacant by the stepping down of Michael Partsch, CEO of Accelemed, Inc., who has been a board member since MyoScience’s initial funding. Mr. Partsch will remain a board observer.
“MyoScience has made great strides since its initial funding,” said Michael Partsch. “I am honored to have been part of that success as a board member and am very excited about the opportunity available to the Company”.
“Mike Partsch has been a valuable board member since our A round of financing,” said Bob Curtis. “We thank him for his seminal contributions to the early success of MyoScience.”
About MyoScience, Inc.
MyoScience, Inc., founded in 2005 with headquarters in Redwood City, California, is a clinical development stage company focused on developing a non-toxic treatment for dynamic facial wrinkles (frown lines between the brows and forehead and crow’s feet lines). MyoScience received 510k clearance from the U.S. Food and Drug Administration for its device in 2009 for a general indication. MyoScience is currently investigating applications in aesthetics. Major investors in MyoScience, include De Novo Ventures, Accuitive Medical Ventures, Nexus Medical Partners, Saratoga Ventures, and Medicis Capital GmbH.
CONTACT: Robert M. Curtis, President and CEO of MyoScience, Inc.,
+1-650-474-2600, bcurtis@myoscience.com
